Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index; 1 of the 16 sources its claims cite were checked for support.

Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study

Open access
Ren, Qingjuan, Zhi, Lei, Liu, Hongfang · 2025 · Drug Design, Development and Therapy

Abstract

Purpose: This study aimed to investigate changes in muscle mass and strength among older adults with type 2 diabetes who were treated with Semaglutide. Methods: This was a retrospective cohort study comparing elderly patients with type 2 diabetes receiving Semaglutide to a matched control group. Changes in muscle mass and function over 24 months were assessed. Muscle mass was measured using the appendicular skeletal muscle mass index (ASMI), while muscle function was evaluated through grip strength and gait speed measurements. Differences between the two groups and changes before and after treatment were analyzed using the t -test. Additionally, multivariable linear regression models were constructed to identify clinical predictors of accelerated muscle loss during Semaglutide treatment. Results: The study involved 220 patients treated with Semaglutide and 212 control subjects. The prevalence of sarcopenia among participants was 27.7%. Semaglutide treatment significantly reduced both body mass index and muscle mass compared to controls. Notably, divergent patterns emerged in functional measures. Grip strength initially improved but then declined in men, while it continued to decrease in women. Gait speed significantly reduced in both genders. Multivariable analysis identified Semaglutide dosage, baseline ASMI, and gait speed as independent predictors of muscle loss. Conclusion: The use of Semaglutide is associated with muscle loss and functional decline in older adults with type 2 diabetes, particularly at higher doses. This effect is especially significant in patients with sarcopenia. Consequently, it is crucial to assess the risks and benefits for each elderly patient individually and to implement appropriate monitoring and interventions. The potential for nutritional supplementation and targeted exercise regimens to counteract semaglutide-associated muscle decline merits systematic investigation. Keywords: older adults, type 2 diabetes, semaglutide, sarcopenia, muscle mass, mass strength

Overview

CoChat Summary

TL;DR

In older adults with type 2 diabetes, 24 months of semaglutide therapy was associated with greater reductions in BMI, muscle mass, handgrip strength, and gait speed than in matched controls. Higher semaglutide dose, lower baseline ASMI, and slower gait speed independently predicted greater muscle loss.

Key findings

  • Among 220 semaglutide-treated patients and 212 matched controls, sarcopenia prevalence was 27.73%; at 24 months the semaglutide group had significantly lower BMI, ASMI, handgrip strength, and gait speed than controls (p<0.05).
  • Cumulative ASMI loss by study end reached 0.39 kg/m² in females and 0.26 kg/m² in males; BMI fell continuously in the semaglutide group (p<0.001), and ASMI reductions became significant from month 12 onward.
  • Handgrip strength in males transiently improved at 6 months then declined; females showed no significant 6-month change followed by significant deterioration. Gait speed showed statistically significant overall reductions in both genders.
  • Multivariable linear regression identified semaglutide dosage, baseline ASMI, and gait speed as independent predictors of muscle loss, while handgrip strength lost statistical significance; the model had R²=0.337.

Methods

  • Retrospective cohort study of patients ≥65 years with T2DM, BMI ≥24 kg/m², and no prior GLP-1RA or DPP-4 inhibitor use, initiating semaglutide at one hospital between January and December 2022; propensity score matching (1:1) used age, sex, baseline BMI, diabetes duration, and comorbidities.
  • Participants were followed for 24 months with data at baseline, 6, 12, 18, and 24 months; muscle mass was measured by ASMI, and function by handgrip strength and 4-meter gait speed.
  • Between-group and longitudinal comparisons used independent and paired t-tests, categorical variables used chi-square tests, and multivariable linear regression identified predictors of muscle loss.

Limitations

  • Stated by the paper: relatively small sample size may limit generalizability; nutritional intake and physical activity patterns were not assessed; and the observational design prevents causal conclusions.
  • Evident from the text: the study was conducted at a single hospital (“our hospital”), which may further limit external validity, and the retrospective source dataset lacked standardized lifestyle assessments.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/dddt.s531778

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Longitudinal changes in BMI and muscle parameters during the study period. (a) BMI trajectories. (b) AMSI changes. (c) Handgrip strength variations. (d) Gait speed dynamics. Compare of Semaglutide group: male #<0.05, ##<0.01, ###<0.001; female #<0.05, ##<0.01, ###<0.001. Compare of control group: male *<0.05, **<0.01, ***<0.001; female *<0.05, **<0.01, ***<0.001.
Figure 1 Longitudinal changes in BMI and muscle parameters during the study period. (a) BMI trajectories. (b) AMSI changes. (c) Handgrip strength variations. (d) Gait speed dynamics. Compare of Semaglutide group: male #<0.05, ##<0.01, ###<0.001; female #<0.05, ##<0.01, ###<0.001. Compare of control group: male *<0.05, **<0.01, ***<0.001; female *<0.05, **<0.01, ***<0.001.CC BY-NC · PubMed Central
Figure 2 Multivariable regression analysis of predictors for muscle mass loss following semaglutide treatment. Semaglutide dosage, ASMI, and Gait speed were significant influences. Muscle mass loss (kg/m2) =1.536 + 0.096 × Semaglutide dosage ‒ 0.076 × ASMI + 0.004 × Hand grip strength ‒ 0.892 × Gait speed (R2=0.337).
Figure 2 Multivariable regression analysis of predictors for muscle mass loss following semaglutide treatment. Semaglutide dosage, ASMI, and Gait speed were significant influences. Muscle mass loss (kg/m2) =1.536 + 0.096 × Semaglutide dosage ‒ 0.076 × ASMI + 0.004 × Hand grip strength ‒ 0.892 × Gait speed (R2=0.337).CC BY-NC · PubMed Central

Verification

Claims the paper makes

1 Valid · 0 Not valid · 13 Not checked · 37 Own results and interpretations

15 references still to check

A free account verifies the references that are still open.

Verify all 15 references — free account
  • Not yet classified. 46
  • It may state two separate claims as one. 3
  • Probably not a substantial claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 19 references

Cited by

See all 44

Metadata

Authors
Ren, Q., Zhi, L., & Liu, H.
Corresponding author
Ren, Qingjuan
Venue
Drug Design, Development and Therapy
Published
2025-07
Volume
Volume 19
Pages
5645-5652
ISSN
1177-8881 (ISSN-L)
OpenAlex
W4411931568
Cited by
44
References
19
Citations by year
2026: 37 · 2025: 7
FWCI
28.31
Type
journal article
Language
en
Open access
Locations
  • Drug Design Development and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
Keywords
semaglutide, sarcopenia, type 2 diabetes, older adults, muscle mass, muscle strength, grip strength, walking speed, appendicular skeletal muscle mass index, muscle mass loss, GLP-1 receptor agonists, body mass index
MeSH terms
Semaglutide, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies, Cohort Studies, Muscle, Skeletal, Hand Strength, Glucagon-Like Peptide 1, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study. https://app.cochat.ai/papers/10.2147/dddt.s531778
The paper
Ren, Q., Zhi, L., & Liu, H. (2025). Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s531778

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.